Photofrin for Endobronchial non-small cell lung cancer
Quick answer: Photofrin is used for Endobronchial non-small cell lung cancer as part of a photosensitizer (photodynamic therapy agent) treatment regimen. Porfimer sodium accumulates in tumor tissue and generates cytotoxic singlet oxygen upon laser light activation The specific dosing for Endobronchial non-small cell lung cancer is determined by your prescriber based on individual factors.
Why is Photofrin used for Endobronchial non-small cell lung cancer?
Photofrin belongs to the Photosensitizer (photodynamic therapy agent) class. Porfimer sodium accumulates in tumor tissue and generates cytotoxic singlet oxygen upon laser light activation This action makes it useful for treating or managing Endobronchial non-small cell lung cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Photofrin is the right choice for a specific patient depends on the type and severity of Endobronchial non-small cell lung cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Endobronchial non-small cell lung cancer
Common adult dosing range: 2 mg/kg IV followed by laser illumination 40-50 hours later. The actual dose for Endobronchial non-small cell lung cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Photofrin medicine page.
What to expect
Photofrin treatment for Endobronchial non-small cell lung cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Endobronchial non-small cell lung cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Photofrin is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Photosensitizer (photodynamic therapy agent) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Photofrin
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Photofrin full prescribing information · All Photosensitizer (photodynamic therapy agent) alternatives
Frequently asked questions
How effective is Photofrin for Endobronchial non-small cell lung cancer?
Effectiveness varies by individual response, dose, and severity. Photofrin is one of several treatment options for Endobronchial non-small cell lung cancer, supported by clinical evidence within the photosensitizer (photodynamic therapy agent) class. Discuss expected response with your prescriber.
How long do I need to take Photofrin for Endobronchial non-small cell lung cancer?
Treatment duration depends on the nature of Endobronchial non-small cell lung cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Photofrin when used for Endobronchial non-small cell lung cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Photofrin for Endobronchial non-small cell lung cancer?
Yes. Multiple medicines and non-drug options exist for Endobronchial non-small cell lung cancer. Alternatives within the photosensitizer (photodynamic therapy agent) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.